勵晶(00575.HK)逆市勁彈82%價量齊創新高 商業夥伴早洩藥獲歐盟批准轉為非處方藥
勵晶太平洋(00575.HK)公布商業夥伴Recordati治療早洩藥獲歐盟批准轉為非處方藥,此舉旨在大幅提升銷量及繼而增加支付給集團之專利權使用費。該股今天逆市突破52周高位0.191元,曾飆升1.1倍至0.24元,創逾13個月高,現造0.204元,急彈82%,一向薄弱成交激增至5.47億股,為多年來罕見,涉資1.07億元。
勵晶太平洋公布,商業夥伴Recordati S.p.A已於8月27日獲歐盟批准,治療早洩藥Fortacin之營銷授權由處方藥轉為非處方藥,此舉旨在大幅提升銷量及繼而增加支付給集團之專利權使用費。Recordati、PSNW 及集團正在探討擴大生產規模之各種方案,以滿足估計對非處方藥之需求,目標是每批量訂單生產約5萬單位,並減少供應鏈短缺及不可靠之風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.